الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
Schistosomiasis continues to occupy the second position in the world among parasites, after malaria, in the term of the extant of endemic areas and number of people infected. In view of more than 40 years of continuous treatment with Praziquantel (PZQ), the only available anti-schistosomal medication, transmission of Schistosoma remains continuous and uninterrupted.
Recently, some researches described proliferating cells scattered throughout the parasite body that are akin to the previously described stem-cell like neoblasts in planarians. It seems that these stem cells are essential to the tissue regeneration of Schistosoma in the host.
The proposal of this work was to exploit the ability of antineoplastic anticancer drugs to stop or retard the mitotic activity, division or proliferation of any dividing cells. Thus, an antineoplastic agent may be an alternative drug against Schistosomiasis, targeting stem cell proliferation and differentiation in schistosome worms, and preventing the regeneration of the parasite. Prevention of regeneration will expose the worm to the host attacks. This may lead to the eradication of the worm.
In the present work, Schistosoma mansoni worms have been exposed to a wide range of concentrations of several antineoplastic drugs (Hydroxyurea, Cisplatin, methotrexate and colchicine) and praziquantel in vitro. Then two drugs were selected (Hydroxyurea and Cisplatin) and, together with praziquantel, were tested in vivo in schistosoma mansoni mouse model.
In conclusion, It is obvious that Hydroxyurea and Cisplatin had anti-schistosome effects. Consequently, these drugs may represent a promising alternative strategy for control of Schistosomiasis mansoni.